(Total Views: 506)
Posted On: 11/30/2021 10:48:21 AM
Post# of 154147
SamaGong,
The mesencure mechanism appears valid, mesenchymal stem cells reducing inflammation (Mesoblast has demonstrated lesser results but in a larger, rigorous trial). These trial results are intriguing but not sufficient IMO.
There are many potential ways to approach reduction of innate immune dysregulation/disproportionate activation.
I don’t believe any are a match for Leronlimab.
The mesencure mechanism appears valid, mesenchymal stem cells reducing inflammation (Mesoblast has demonstrated lesser results but in a larger, rigorous trial). These trial results are intriguing but not sufficient IMO.
There are many potential ways to approach reduction of innate immune dysregulation/disproportionate activation.
I don’t believe any are a match for Leronlimab.
(9)
(0)
